Bain Capital has amassed $720 million for its first investment fund to exclusively focus on opportunities in the life sciences sector. The new fund, named Bain Capital Life Sciences, will be led by former Biogen strategy executive Adam Koppel and invest between $30 and $70 million into private and public live sciences companies engaged in everything from medical devices to specialty pharmaceuticals and biotech, according to a Reuters article.